The FDA on Tuesday approved Bayer's Nubeqa (darolutamide) as a monotherapy for metastatic castration-sensitive prostate cancer (mCSPC). The US regulator had previously cleared the androgen receptor inhibitor in combination with docetaxel for the same patient population. The green light was based on results of the Phase III ARANOTE study, which were presented at last year's European Society for Medical Oncology (ESMO) congress. The trial enrolled 669 patients with mCSPC who were either taking sta

Having secured approval in BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), Johnson & Johnson's Akeega (niraparib/abiraterone) has now produced positive findings in patients with castration-sensitive disease, including an early trend toward improved overall survival (OS). However, the benefit was greater in a subgroup of participants, raising questions about the path forward.The latest data come from the Phase III AMPLITUDE study, which randomised 696 patients with metastat

Sanofi presented positive clinical data Tuesday for a subcutaneous (SC) formulation of its multiple myeloma drug Sarclisa (isatuximab) at the American Society of Clinical Oncology (ASCO) annual meeting, offering hope for the French drugmaker's efforts to grab more market share from Johnson & Johnson's dominant Darzalex (daratumumab) franchise.While Darzalex generated $11.7 billion in sales last year compared to Sarclisa's $471 million, the new data suggest Sanofi's SC approach – using an on-body

Looking to bounce back after its lead depression programme failed in a Phase II trial last year, Alto Neuroscience announced a small deal with Chase Therapeutics Tuesday through which it acquires a dopamine agonist combination product for treatment-resistant depression.ALTO-207, formerly CTC-501, combines pramipexole – a dopamine receptor agonist approved for Parkinson's disease – with the anti-nausea medication ondansetron in a fixed-dose formulation designed to enable higher dosing of pramipex

SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinic

SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer at the 2025 American Society of Clinical O

SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and all

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed by Remegen Co., Ltd., and toripalimab (PD-1) combined with CAPOX or trastuzumab as the first-line therapy for HER2-expressing patients with locally advanced or metastatic (la/m) gastric canc

Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases and drug discovery TOKYO, June 2, 2025 /PRNewswire/ -- Sony Semiconductor Solutions Corporation (Sony), SCREEN Holdings Co., Ltd. (SCREEN), and VitroVo Inc. (VitroVo) today announced that they have jointly developed and will offer on a trial basis a microelectrode array (MEA) system powered by high-density CMOS-MEA*1 equipped with approximately 237,000 electrodes. Combini

BEIJING, June 2, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes of JensClip, a proprietary TMVr system, at EuroPCR 2025 in Paris, France. 30-Day Follow-up Results of LuX-Valve Plus TRINITY Study TRINITY is a global prospective, multicenter, single-arm clinical trial, which p